LifeStance Health Group Inc (NASDAQ: LFST)’s stock price has soared by 0.40 in relation to previous closing price of 5.04. Nevertheless, the company has seen a loss of -9.64% in its stock price over the last five trading days. zacks.com reported 2025-06-16 that The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is It Worth Investing in LifeStance Health Group Inc (NASDAQ: LFST) Right Now?
LFST has 36-month beta value of 1.22. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LFST is 116.86M, and currently, short sellers hold a 7.84% ratio of that float. The average trading volume of LFST on June 18, 2025 was 1.83M shares.
LFST’s Market Performance
LFST stock saw a decrease of -9.64% in the past week, with a monthly decline of -13.36% and a quarterly a decrease of -25.70%. The volatility ratio for the week is 0.67%, and the volatility levels for the last 30 days are 2.84% for LifeStance Health Group Inc (LFST). The simple moving average for the past 20 days is -10.80% for LFST’s stock, with a -27.47% simple moving average for the past 200 days.
Analysts’ Opinion of LFST
Many brokerage firms have already submitted their reports for LFST stocks, with UBS repeating the rating for LFST by listing it as a “Buy.” The predicted price for LFST in the upcoming period, according to UBS is $8.50 based on the research report published on May 27, 2025 of the current year 2025.
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see LFST reach a price target of $9. The rating they have provided for LFST stocks is “Overweight” according to the report published on April 08th, 2025.
Canaccord Genuity gave a rating of “Buy” to LFST, setting the target price at $8 in the report published on April 03rd of the current year.
LFST Trading at -16.56% from the 50-Day Moving Average
After a stumble in the market that brought LFST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.23% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LFST starting from Ramtekkar Ujjwal, who proposed sale 9,519 shares at the price of $5.17 back on Jun 16 ’25. After this action, Ramtekkar Ujjwal now owns shares of LifeStance Health Group Inc, valued at $49,213 using the latest closing price.
Ramtekkar Ujjwal, the Chief Medical Officer of LifeStance Health Group Inc, sale 16,000 shares at $5.94 during a trade that took place back on Jun 05 ’25, which means that Ramtekkar Ujjwal is holding 113,435 shares at $95,040 based on the most recent closing price.
Stock Fundamentals for LFST
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.3 for the gross margin
The net margin for LifeStance Health Group Inc stands at -0.03. The total capital return value is set at -0.01. Equity return is now at value -2.47, with -1.69 for asset returns.
Based on LifeStance Health Group Inc (LFST), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.64. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -0.54.
Currently, EBITDA for the company is 39.87 million with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 1.58. The receivables turnover for the company is 9.14for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
To put it simply, LifeStance Health Group Inc (LFST) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
